Results 251 to 260 of about 592,769 (337)

National Trends in Admissions, Treatments, and Outcomes for Dilated Cardiomyopathy (2016-2021). [PDF]

Med Sci (Basel)
Varughese VJ, Mohamed A, Nagesh VK, Atoot A.   +3 more
europepmc   +1 more source

A case of dilated cardiomyopathy in intractable heart failure stage which pimobendan additive therapy and combined additive therapy with denopamine showed significant efficacy.

, 1992
藤田 俊夫, 津田 隆志, 野中 麗永, 宮島 武文, 田中 吉明, 小玉 誠, 和泉 徹, 柴田 昭   +7 more
openalex   +2 more sources

Usefulness of Plasma Branched-Chain Amino Acid Analysis in Predicting Outcomes of Patients with Nonischemic Dilated Cardiomyopathy

, 2020
Yuki Kimura, Takahiro Okumura, S. Kazama, Naoki Shibata, Hideo Oishi, Yoshihito Arao, Tasuku Kuwayama, Hiroo Kato, Shogo Yamaguchi, Hiroaki Hiraiwa, Toru Kondo, Ryota Morimoto, Toyoaki Murohara   +12 more
openalex   +2 more sources

P3248Investigating dilated cardiomyopathy caused by dystrophin mutations using duchenne muscular dystrophy-patients induced pluripotent stem cell-derived cardiomyocytes [PDF]

, 2017
Binyamin Eisen, Ronen Ben Jehuda, Lucy N. Mekies, Yuval Shemer, Ashley J. Cuttitta, Lorenzo Monserrat, Mihaela Gherghiceanu, Michael Arad, Dov Freimark, Daniel E. Michele, Ofer Binah   +10 more
openalex   +1 more source

Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience

European Journal of Heart Failure, 2018
A. Fornaro, I. Olivotto, L. Rigacci, M. Ciaccheri, B. Tomberli, C. Ferrantini, R. Coppini, F. Girolami, F. Mazzarotto, M. Chiostri, Massimo Milli, N. Marchionni, G. Castelli   +12 more
semanticscholar   +1 more source

Late Gadolinium Enhancement Variation in Asymptomatic Individuals: Comparison with Dilated Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Park S, Cho SJ, Kim SM, Kim MY, Choe YH.
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

T2 mapping cardiovascular magnetic resonance identifies the presence of myocardial inflammation in patients with dilated cardiomyopathy as compared to endomyocardial biopsy [PDF]

, 2017
Maximilian Spieker, Efstratios Katsianos, Mareike Gastl, Patrick Behm, Patrick Horn, Christoph Jacoby, Bernhard Schnackenburg, P. Reinecke, Malte Kelm, Ralf Westenfeld, Florian Bönner   +10 more
openalex   +1 more source

Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future

Circulation, 2017
B. Halliday, J. Cleland, J. Goldberger, S. Prasad   +3 more
semanticscholar   +1 more source

Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis

British Journal of Pharmacology, EarlyView.
Background and Purpose Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments remain scarce.
Sheyla Barrado‐Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen, Casper Gravesen Salinas, Urmas Roostalu   +11 more
wiley   +1 more source